阿尔茨海默病星形胶质细胞来源外泌体中补体水平升高
研究从阿尔茨海默病(AD)患者和匹配对照的血浆中免疫化学分离星形胶质细胞来源外泌体(ADE),用酶联免疫吸附试验定量补体蛋白。AD患者ADE中多种补体效应蛋白水平显著高于对照(均p<0.0001),而补体调节蛋白CD59和DAF显著降低;纵向研究中AD2阶段补体蛋白水平显著高于AD1阶段。
要点
- AD患者ADE补体效应蛋白C1q、C4b、C3d、因子B、因子D、Bb、C3b、C5b-C9显著高于对照(均p<0.0001)。
- AD患者ADE补体调节蛋白CD59和DAF显著低于对照(p<0.0001)。
- 纵向研究AD2阶段补体蛋白水平显著高于AD1阶段(n=16,p<0.0001)。
核心结论
- AD中ADE补体效应蛋白由失调系统产生,达到高于对照的水平,并可能在AD晚期炎症阶段损伤神经元。
研究设计与样本
- 从AD患者和匹配对照的血浆样本中免疫化学分离星形胶质细胞来源外泌体(ADE),用酶联免疫吸附试验定量补体蛋白。
主要发现
- AD患者(n=28)ADE中C1q、C4b、C3d、因子B、因子D、Bb、C3b和C5b-C9终末补体复合物经CD81外泌体标记归一化后显著高于年龄和性别匹配对照(均p<0.0001),甘露糖结合凝集素无显著差异。
- AD患者ADE中白细胞介素-6、肿瘤坏死因子-α和白细胞介素-1β归一化水平显著高于对照,但两组重叠大于补体蛋白。
- 纵向研究中AD患者(n=16)中度痴呆AD2阶段ADE补体蛋白平均 levels 显著高于5至12年前临床前AD1阶段(p<0.0001),AD1阶段与对照相同。
- AD患者ADE补体调节蛋白CD59、CD46、衰变加速因子(DAF)和补体受体1型显著低于对照(CD59和DAF的p<0.0001),因子I无显著差异;这些调节蛋白在AD1阶段已降低,AD2阶段进一步降低。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Astrocytes fulfill neuronal trophic roles normally, but are transformed in Alzheimer disease (AD) into A1-type reactive astrocytes that may destroy neurons through unknown mechanisms. METHODS: To investigate astrocyte inflammatory mechanisms, astrocyte-derived exosomes (ADEs) were isolated immunochemically from plasma samples of AD patients and matched controls for enzyme-linked immunosorbent assay quantification of complement proteins. RESULTS: ADE levels of C1q, C4b, C3d, factor B, factor D, Bb, C3b, and C5b-C9 terminal complement complex, but not mannose-binding lectin, normalized by the CD81 exosome marker were significantly higher for AD patients (n = 28) than age- and gender-matched controls (all p < 0.0001). ADE normalized levels of interleukin (IL)-6, tumor necrosis factor-α, and IL-1β were significantly higher for AD patients than controls, but there was greater overlap between the two groups than for complement proteins. Mean ADE levels of complement proteins for AD patients in a longitudinal study were significantly higher (n = 16, p < 0.0001) at the AD2 stage of moderate dementia than at the AD1 preclinical stage 5 to 12 years earlier, which were the same as for controls. ADE levels of complement regulatory proteins CD59, CD46, decay-accelerating factor (DAF), and complement receptor type 1, but not factor I, were significantly lower for AD patients than controls (p < 0.0001 for CD59 and DAF), were diminished by the AD1 stage, and were further decreased at the AD2 stage. INTERPRETATION: ADE complement effector proteins in AD are produced by dysregulated systems, attain higher levels than in controls, and may potentially damage neurons in the late inflammatory phase of AD. Ann Neurol 2018;83:544-552.
引用
- Goetzl EJ, Schwartz JB, Abner EL, et al. High complement levels in astrocyte-derived exosomes of Alzheimer disease. Ann Neurol. 2018. PMID: 29406582. doi:10.1002/ana.25172
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。